VOLITIONRX LTD (VNRX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US9286612067
VOLITIONRX LTD financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.73 m USD |
| Operating income | -21.74 m USD |
| EBIT | -23.36 m USD |
| Net income | -23.36 m USD |
Full history since 2004, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About VOLITIONRX LTD
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
More stocks
- EXICURE, INC. (XCUR)
- BTC Digital Ltd. (BTCT)
- T3 Defense Inc. (DFNS)
- Armlogi Holding Corp. (BTOC)
- Theriva Biologics, Inc. (TOVX)
- Sadot Group Inc. (SDOT)
- Aprea Therapeutics, Inc. (APRE)
- Chinhung International Inc (002785.KS)
- Zoned Properties, Inc. (ZDPY)
- CNS Pharmaceuticals, Inc. (CNSP)
- AiXin Life International, Inc. (AIXN)
- Saker Aviation Services, Inc. (SKAS)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.